Sustained Release Oral Formulation for Treatment of Parkinson's Disease

Phase 0 Completed 6 enrolled University of Minnesota

RandomizedSingle-groupDouble-blindTreatment

Summary

Achieving sustained blood levels of carbidopa/levodopa has been a challenge in the treatment of PD and although levodopa remains the most commonly used drug, motor fluctuations remain a major disability especially in advanced Parkinson's disease. The aim of this study is to determine the efficacy of a novel oral carbidopa-levodopa formulation in achieving a sustained blood level of levodopa and carbidopa in normal volunteers.

Timeline

Start: 2025-06-12
Primary completion: 2025-08-14
Completion: 2025-08-14

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carbidopa	Unknown	100 mg	Oral
Subject	Levodopa	Small molecule	400 mg	Oral

Indications

No indication recorded.